




Australian Biotech Mission BIO Asia-Taiwan 2023



AUSTRALIA

Sponsors

Australian Government Department of Home Affairs



👤 Pip Butler, First Secretary, Global Skills
Attraction North and South-East Asia

☎ +886 2 8725 4121

✉ globalskillsnorthasia@dfat.gov.au

🌐 www.smartmoveaustralia.gov.au

Company Introduction

Australia is not unique in experiencing skill shortages, and there is tough competition across the globe to attract skilled migrants.

Australia is focused on attracting the best and brightest to our country and we offer a range of visas which allow you to pursue your dreams.

To support you to discover what Australia has to offer, the Australian Government's Global Skills Attraction Officers are here to help. We provide information on visa programs and tips on how to get your visa application right the first time, which will help with faster processing times.

Australia has so much to offer you and your

family, we are a smart nation that works hard and plays hard. Our country is safe, with multiculturalism and diversity at our cultural core. Our environment is clean and green, perfect for all manner of recreational and social activities, and we have a first-class education system which is ensuring that our children are future ready.

If you would like to know more about what you need to do to start your Australian adventure, visit the visa finder page on our website, email us at globalskillsnorthasia@dfat.gov.au or chat to a Global Skills Attraction Officer at the Australian Pavilion at Bio-Asia Taiwan.


Areas of Interest in Taiwan market


Biotech, MedTech and Health Professionals (Allied Health Doctors, Nurses etc)



 Lawrence Chang, NSW Trade and Investment Director Taipei Post

 +886 2 8758 4215

 lawrence.chang@austrade.gov.au

 investment.nsw.gov.au

Company Introduction

New South Wales, Australia: A global hub for health and life sciences

With Australia's largest population, strongest economy, and innovative life sciences sector, New South Wales (NSW) is home to an integrated, world-class health and medical research sector that is solving some of the world's most complex and burdensome healthcare challenges.



With an annual operating budget of AU\$30.2 billion, the NSW public health care system offers world-class care to our 8 million citizens through 228 public hospitals.



NSW is home to 11 universities, with 2 ranked in the top 50 for medicine and health. Australia is ranked 8th in the world for life sciences research.



Government R&D tax incentives for eligible companies make early-phase clinical trials 60 percent cheaper to run in Australia than the US.



Precincts are a strength of NSW's health system. Across the state there are globally significant networked concentrations of health, research, and education facilities.



The state's health and medical research ecosystem is backed by the NSW Government; with AU\$11.9 billion in capital investment over four years to 2025-2026, and a range of grants.



Home to 55 percent of Australia's MedTech and biotech companies, and 44 percent of startups. First-choice location of Australian HQ for multinationals. 5th in the world for biotech capabilities.

With business, hospitals, universities, clinics, and research institutes collaborating across multiple dedicated locations, NSW is leading the way to a healthier future for everyone. NSW is open for business, and we welcome you to join us in driving innovation and improving health outcomes.

Delegates

360biolabs Pty Ltd



👤 Sharon Sim, Senior Business Development Manger
☎ +61 423 536 881
✉ sharon.sim@360biolabs.com
🌐 www.360biolabs.com

Company Introduction


360biolabs is a specialty laboratory supporting the clinical trial sector. We support pharmacokinetic (PK) analysis (biologics, small molecules, peptides and proteins), a diverse range of pharmacodynamic (PD) endpoints (including but not limited to flow cytometry, biomarkers, molecular assays, ELISPOT, virological endpoints including neutralisation)

and central lab services in a quality assured environment (GLP, GCP, ISO / IEC 17025).

360biolabs is looking to engage with biotech/ pharmaceutical companies to encourage companies to conduct their clinical trials in Australia and utilise 360biolabs services.

Areas of Interest in Taiwan market

Clinical trial, Bioanalysis, Pharmacodynamics, Pharmacokinetics



ACCLIME

ACCLIME.

👤 Blair Lucas
Group Commercial Director

☎ +61 403 358 638

✉ b.lucas@acclime.com

🌐 australia.acclime.com

Company Introduction

Acclime Australia provides incorporation, compliance, accounting, tax, and advisory services for life science companies doing clinical trials in Australia that have also decided to access the country's R&D incentive program, which can give 43.5 cents cash back all every dollar spent on eligible R&D in Australia.

Acclime also has decades of experience working with clients in the life sciences and healthcare space - across a range of therapeutic areas - in providing both Market Entry Advisory Services and post-market entry Corporate Services throughout Asia, including:

- Opportunity assessment and pre-sales advice
- Strategic road maps and business plans
- Company incorporations, Resident Directors, Accounting & Tax services, etc

Our Market Entry Advisory Service offering includes advising on partnerships from preclinical evaluation to post-marketing commercialisation, thereby covering all clinical trial phases (I to IV). Acclime has also managed product registrations and other macro regulatory requirements for new drugs and devices across Asia.

Areas of Interest in Taiwan market

Clinical trials, product registration, partner identification, R&D Tax Incentives

AcuraBio Pty Ltd



👤 Carolyn Cheer
VP Business Development

☎ +61 499 521 678

✉ carolyn.cheer@acurabio.com

🌐 www.acurabio.com

Company Introduction

AcuraBio Pty Ltd is one of Australia's most experienced microbial fermentation CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years.

Leveraging decades of expertise in microbial expression systems, AcuraBio's service offerings include Recombinant Protein, Live Biotherapeutics/Microbiom and Bacterial Vaccines. AcuraBio is now adding plasmid DNA

services to its service offering, offering pDNA for mRNA vaccines, viral vector manufacture, DNA vaccines and gene therapeutics.

World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research.

Additional information about AcuraBio is available at www.acurabio.com

Areas of Interest in Taiwan market

pDNA, Live Biotherapeutics, Microbiome, Recombinant Protein, Bacterial Vaccines

CMAX Clinical Research



👤 Zoe Harrison, Chief Business Development Officer

☎ +61 403 594 741

✉ zoe.harrison@cmx.com.au

🌐 www.cmx.com.au

Company Introduction

CMAX Clinical Research has been a leader in delivering early phase clinical trials for 30 years, making it one of the most respected clinical trial businesses in Australia.

Our modern custom-built facility is equipped with 78 inpatient beds and located opposite Adelaide's Bio-Med City, providing ready access to state-of-the-art facilities, equipment and world-class medical specialists.

Australian clinical trials are known for their quick start-up timelines, cost competitiveness and for their quality. CMAX's services are eligible for the generous Australian R&D Tax Incentive scheme. Australian data is internationally recognised by the FDA and other regulatory agencies.

Areas of Interest in Taiwan market

We are interested in potential collaborations with Taiwanese and other international biopharmaceutical companies who are

preparing for early phase clinical trials and are interested in the benefits of conducting their trial in Australia.

CSI Medical Research



CSI Medical Research
we bring innovation to trials

👤 Nelson Wong, CEO

☎ +65 9641 0095

✉ Nelson.wong@csimedicalresearch.com

BD@csimedicalresearch.com

🌐 www.csimedicalresearch.com

Company Introduction

Clinical Solutions Innovating Medical Research aka CSI Medical Research Pte Ltd (CSI MR) is a contract research organisation (CRO) providing innovative, cost-effective, and efficient clinical solutions since 2017. We believe in implementing innovative automation by focusing on patient safety and care in clinical trials.

CSI MR has extensive industry experience and knowledge of local practices, regional ethics, regulatory requirements, and site operations, making us your preferred strategic partner. We hope to aid more companies to confidently

enter the ASEAN market with us for innovative and cost-effective solutions.

We provide clinical research services from strategy and proof of concept to medical writing, project management, clinical operations, pharmacovigilance, medical monitoring, data management and market authorization. We use our strong network of providers and partners to support your clinical research. Our clients range from biotechs, biopharmaceuticals, medical devices and clients looking for expertise to conduct their research and market authorization.

Areas of Interest in Taiwan market

Clinical trials, pharmaceutical, medical devices, medical innovations, market authorization

Explor Biologics



👤 Dr. Joshua Chou, CEO/ Co-Founder

☎ +61 423 257 471

✉ josh@explorbiologics.com

🌐 www.explorbiologics.com

Company Introduction

EXPLOR Biologics is the world's first space biotechnology company that has developed a space-based bioreactor that can enhance the biomanufacturing of key biologics in cosmetics, regenerative medicine, stem cell therapies, exosomes, synthetic biology, bacterial and viral products.

Through EXPLOR Biologics disruptive technology, world leading pharmaceutical, cosmetic and biotechnology companies are

developing next leading products and solutions in different areas of human healthcare.

EXPLOR Biologics was established and based in Sydney, Australia and has presence now in Michigan, United States and in Tokyo, Japan.

EXPLOR Biologics continue to seek strong collaborative partnerships with different industries, and we are passionate to bring our technology to add value for our partners.

Areas of Interest in Taiwan market

Biomanufacturing, cosmetics, regenerative medicine, stem cells, therapeutics, exosomes

Company Introduction

Founded in Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical has been a leading, global clinical research organization for more than 20 years. With over 450 experienced people in 19 locations able to manage clinical trials in up to 70 geographies throughout the Asia-Pacific region, USA and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device and diagnostic customers, for all phases, registration and post-marketing trials

George Clinical provides a full scope CRO services. We have the flexibility to provide single services as well as a full scope trial management solution to suit the requirements of our clients ranging from biotech start-ups, pharmaceutical, medical devices and academic institutions.

Our unique value proposition combines

scientific expertise with operational excellence. Through our panel of scientific leaders, many of whom are leading thought leaders in their respective fields, we have access to extensive investigator networks in a number of therapeutic areas including kidney & metabolic, cardiovascular, neurology and oncology.

Australia offers unique advantages for Taiwanese pharmaceuticals and biotech companies conducting early phase studies with its fast start-up timeline, well established Phase I units, experienced investigators, high quality data that is well recognized globally and an attractive R&D tax incentive scheme. George Clinical are well positioned to help Taiwanese sponsors take advantage of these operational benefits and look forward to having those conversations with the biotech, pharma and medical devices companies at BIO-Taiwan.

GreenLight Clinical



GreenLight Clinical

👤 Dr Robert Lin, CEO

☎ +61 2 9191 0640

+61 417 655 921

✉ Robert.Lin@greenlightclinical.com

🌐 www.greenlightclinical.com

Company Introduction

GreenLight Clinical is a physician-led, boutique full-service clinical CRO based in Sydney, Australia. We have offices in Australia and USA, with a presence in the APAC region. We help you take advantage of the speed of study start-up and R&D tax incentives in Australia and allow for a smooth trial transition in the US and APAC.

Combining medical expertise and deep industry knowledge, we develop bespoke solutions to accelerate your innovative treatment development for patients with unmet needs, one trial at a time.

Areas of Interest in Taiwan market

Biopharma companies looking for CRO services to conduct their clinical trials in Australia or the USA.

Companies conducting clinical trials in Australia

/ Asia Pacific region taking advantage of comprehensive laboratory services in this region that can be integrated with or standalone from our CRO services.

Novotech



👤 Hsuan-Kai (Calvin) Tzeng, Regional
Director Business Development

☎ +886 928 001 774


✉ calvin.tzeng@novotech-cro.com

🌐 novotech-cro.com


Company Introduction

Novotech is internationally recognized as the leading Asia Pacific centred Biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in

over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.



Nucleus Network Pty Ltd



👤 Jeffery Wong, Director of Business Development

☎ +61 411 314 502

✉ j.wong@nucleusnetwork.com.au

🌐 www.nucleusnetwork.com

Company Introduction

Nucleus Network is Australia's largest Phase 1 clinical research organisation and the only Phase 1 specialist globally with facilities in the USA and Australia. Since our establishment in 2003, Nucleus Network has conducted well over 1000 Phase 1 clinical trials for some of the most reputable Biotechnology and Pharmaceutical Companies from around the world.

Our facilities are located in Brisbane, Melbourne, and Minneapolis. Combined, our clinics have over 200 beds. All three clinics are strategically co-located within leading medical, research and biotech precincts; the Alfred Hospital in Melbourne, the Royal Brisbane and

Women's Hospital in Brisbane, and Medical Alley in Minneapolis. These precincts offer an expanded capability to administer trials safely and effectively, in partnership with relevant collaborative businesses.

Nucleus specialises in early phase clinical pharmacology clinical trials such as First in human SAD/MAD/FE, DDI, ethnobridging, biosimilar, BE/BA and vaccine programs.

With Australia's beneficial speed, quality and cost outcomes resulting in increased interest from globally, Nucleus Network are looking to create robust, long term business relationships with potential clients and sponsors.

Areas of Interest in Taiwan market

Biotechnology Companies, Pharmaceuticals Companies, Early phase clinical trials, Biosimilar, Vaccine

Oculus Biomed Limited



Oculus BioMed Limited

👤 Andrew J. (Medici) COLORETTI,
Executive Director & CEO

☎ + 61 488 083 967

✉ andrew.coloretti@oculusbiomed.com.au

🌐 www.oculusbiomed.com.au

Company Introduction

- Oculus BioMed Limited (“OBM”) is an Australian biomedical company and based in City of Melbourne, Victoria State, Australia.
- OBM specialises in developing novel therapeutic drugs and Medical devices to treat high-prevalence ocular diseases and conditions.
- OBM owns a portfolio of projects with global exclusive rights for the treatment of retinal and cornea disorders. Family of global patents which cover the molecules and the uses have all been granted in major countries and regions.


Areas of Interest in Taiwan market


- Projects of in-licensing and out-licensing opportunities.
- Investors and collaborating partners.

PCI Pharma Services



 Jon Fairweather, Business Development Executive

 +61 401 288 279

 Jon.fairwahrer@pci.com

 www.pci.com

Company Introduction

PCI is a leading global CDMO, providing integrated end-to-end drug development, manufacturing and packaging solutions, increasing product speed to market and commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of supply chain pharmaceutical services. With 30 sites globally, our mission is to collaborate with our clients and deliver life-changing therapies to patients.

PCI's Australia (Melbourne) facility is a destination of choice for drug product supply due to our reputation in providing unmatched flexibility, a client-centric experience and consultative approach, delivering a seamless clinical service.

We offer GMP services in sterile manufacture for a broad range of injectables including mAbs, proteins, peptides, oligonucleotides, mRNA, nanoparticles and other biologic, as well as small molecule solutions. Our low-risk robotic isolator sterile fill-finish technology is ideal for achieving the highest levels of sterility assurance for FTIH dosing, and scalable technology to allow rapid tech transfer from Phase I to Phase 2/3.

Simplifying the clinical supply chain, we can pack and label your valuable IMP, provide full release for supply and distribution to trial sites, ensuring your life-changing drug product reaches patients when needed.

Areas of Interest in Taiwan market

CDMO, Biologics, Biosimilars, Oncology, Small molecules, High potent, Clinical Trials

Scientia Clinical Research



👤 Lisa Nelson, CEO

☎ +61 438 008 816

✉ bdenquiries@scientiaclinicalresearch.com.au

🌐 www.scientiaclinicalresearch.com.au

Company Introduction

Scientia Clinical Research (SCR) is a FDA audited, not-for-profit early phase clinical trial company. SCR operates a 30-bed phase I unit co-located within the Prince of Wales Hospital a tertiary teaching hospitals offering a full range of clinical specialties.

SCR conducts approximately 40 clinical trials per year, the majority being First Time In Human (FTIH) single and multiple dose studies, food effect studies, drug interaction studies, ethnopharmacology studies (Korean, Chinese, Japanese), biosimilar studies, formulation studies and specialty studies incorporating a range of pharmacodynamic markers such as Flow Cytometry and Cytokine analysis.

These studies are being performed in healthy volunteers as well as patient populations such

as oncology, haematology, parkinson's disease, diabetes, fibrosis, atopic dermatitis, and NASH. The majority of our sponsors are multinational pharmaceutical and biotechnology companies.

Australia has a fast & pragmatic clinical trial approval scheme. All clinical trials are submitted to the local Ethics Committee for review. SCR ethics review cycle is approximately 4-6 from submission to approval. This allows first dosing to occur 6-8 weeks from submission to Ethics.

SCR can manufacture finished product (investigational product) from active pharmaceutical ingredients and manage investigational product importation, receipt and labelling. These services have provided significant time and cost savings to our Sponsors.

Areas of Interest in Taiwan market

Early Phase Clinical Trials

Southern Star Research Pty Ltd



David Lloyd, Managing Director
+61 2 9011 6266
david@southernstarresearch.com
southernstarresearch.com

Company Introduction

Southern Star Research is a full-service, Australian clinical research organisation (CRO) with experience in Phase I to Phase IV studies.

We specialise in supporting biotechnology sponsors accelerate their early phase (PhI/II) projects and position their asset for later phase growth.

From developing your protocol, through to crafting the study report, our team of experts help you navigate all aspects of the clinical process. Whether it's a First in Human (FIH), Phase Ib or a large multinational Phase III (PhIII), we'll help you deliver a successful and cost-effective project.

Areas of Interest in Taiwan market

Seeking to expand our brand and network in Taiwan for 2 reasons: preparing for our expansion into Taiwan and to secure Taiwan

based clients who are interested in running a study in Australia